Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
A Phase I Study of Venetoclax Combined With Vyxeos (CPX-351) for Children, Adolescents and Young Adults With Relapsed or Refractory Acute Leukemia
Sponsor: Children's Hospital Medical Center, Cincinnati
This PHASE1 trial investigates Leukemia and is currently actively recruiting participants. Children's Hospital Medical Center, Cincinnati leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Jun 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 11 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2023 — Feb 2024 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Sep 2022 — May 2023 [monthly]
Suspended PHASE1
-
Feb 2022 — Sep 2022 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Dec 2020 [monthly]
Recruiting PHASE1
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — May 2020 [monthly]
Recruiting PHASE1
-
Mar 2019 — Nov 2019 [monthly]
Recruiting PHASE1
First recorded
Dec 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital Medical Center, Cincinnati
For direct contact, visit the study record on ClinicalTrials.gov .